NIH Funding — $1.2 Billion at Risk

Philadelphia pulled $1.2B in NIH funding in 2024, more than most city agencies spend. Penn alone could lose $250M a year to proposed federal cuts.

Lab benchtop with microscope slides, pipette tips, vials, and a budget ledger showing a circled dollar figure.

Philadelphia received over $1.2 billion in NIH funding in 2024 — $1.22 billion for the city proper, per NIH’s own database, and almost $1.3 billion for the region by CBRE’s count. Call it $1.2B for round numbers. That figure is larger than the individual budgets of most city agencies. It funds researchers at Penn, at CHOP, at Temple, at Jefferson. It pays salaries. It buys equipment. It pays for the clinical trials that bring experimental treatments to actual patients. It is, in a very concrete sense, the economic foundation on which Philadelphia’s identity as a research city was built.

Now consider what happens when that number faces a federal budget cycle that has already shown itself willing to make sweeping cuts without warning. The clearest case is the February 2025 NIH directive capping indirect cost reimbursement at 15% — a single federal action that Penn said would cost the university nearly $250 million per year. The Daily Pennsylvanian put the figure slightly lower, at $240 million based on the FY2026 budget projection. That is Penn specifically. It does not include CHOP, Temple, Jefferson, or the smaller research institutions scattered throughout the region.

$250 million per year is not a line item. It is a category of loss that cascades through an institution. Graduate student positions disappear. Postdocs lose their fellowships. Lab equipment purchases get deferred. Senior researchers who built their careers around a specific funding stream find themselves adrift. The people who were in the middle of a five-year study discover that the study can no longer be funded, and the data they collected becomes orphaned.

Philadelphia's economic identity is built on this. Not manufacturing. Not finance, really. Research. The institutions that anchor University City, that employ thousands of highly educated workers, that attract companies looking to tap into a research ecosystem — all of it depends on a flow of federal research dollars that a single budget cycle could severely disrupt.

This is not an abstract policy concern. It is a question about what Philadelphia becomes if the research institutions contract. If Penn loses 250 million annually, it does not simply absorb the loss gracefully. It cuts programs. It reduces faculty. It scales back expansion plans. The companies that located near Penn's research facilities to take advantage of proximity to scientists and clinicians begin to reconsider.

Philadelphia’s response to this vulnerability has been muted. There have been statements from institutional leaders. There has been lobbying. But the fundamental issue is that the city built its economic identity on a foundation that depends almost entirely on the continued goodwill of a federal government that has shown it can change course rapidly and without regard for local consequences.

And the city’s own balance sheet is not reassuring on this front either. The Controller’s office found that Philadelphia was assembling the Comprehensive Annual Financial Report — the document that closes the books on a roughly $4.4 billion General Fund — in Lotus 1-2-3 spreadsheets. A research economy that depends on federal goodwill is fragile enough; pairing it with a city whose books cannot even distinguish a data-entry error from a deliberate withdrawal is a structural risk that compounds the funding exposure.

Philadelphia survives without NIH funding. That's not the question. The question is what Philadelphia becomes when the research institutions contract—when programs shut down, when companies relocate to cities where the ecosystem remained intact. That identity was built over decades. A single budget cycle could diminish it.


Notes, Sources, and Methodology

NIH RePORTER’s own FY2024 by-organization table sums to $1.217 billion across 33 Philadelphia organizations and 2,249 awards, which is where the $1.2B in this article comes from. CBRE’s Global Life Sciences Atlas profile for Philadelphia puts the regional figure at "almost $1.3 billion" for FY2024, the seventh-highest NIH allocation in the U.S. Underlying award-level data by institution is available through NIH RePORTER, the federal database of NIH-funded projects. CHOP alone received $163.7M across 293 NIH awards in FY2024; Penn received $691.2M across 1,298.

The $250M Penn figure refers specifically to the February 2025 NIH directive capping indirect cost reimbursement at 15%, not the broader FY2026 budget proposal. Penn’s own statement to the press was that the directive would cost the university nearly $250 million per year; City & State PA reported the same figure. The Daily Pennsylvanian put the number slightly lower, at $240M, based on the FY2026 budget projection — the lower bound of the estimate. (A third figure, $170.9M, is what Penn said it would lose in the remainder of calendar 2025 alone.) The directive was NIH’s Supplemental Guidance NOT-OD-25-068, issued Feb. 7, 2025. A district court blocked it in March 2025 and converted the injunction into a permanent nationwide one on April 4, 2025; the First Circuit affirmed on January 5, 2026 and issued its mandate on February 27, 2026. **The cap was never implemented.**

The reporting on Penn’s response — faculty ordered to halt $175M in research, a plan to reduce graduate admissions by a third, the Perelman School of Medicine facing a separate $140M exposure — comes from WHYY (Mar 25, 2025) and the Philadelphia Inquirer (Feb 27, 2025). The "at risk" framing in this article’s title refers to the proposed and contested federal actions, not to realized cuts; as of mid-2026, no institution in Philadelphia has reported an actual $1.2B aggregate loss, and the indirect-cost cap that drove the February 2025 headlines was permanently enjoined before it took effect.